Overview
Mooren ulcer is a rare, chronic, painful, progressive ulcerative condition of the cornea (the clear front surface of the eye). It is characterized by peripheral corneal ulceration that typically begins at the limbus (the border between the cornea and the white of the eye) and progresses circumferentially and then centrally, potentially leading to severe vision loss or even perforation of the cornea. The ulcer is idiopathic but is believed to involve an autoimmune mechanism in which the body's immune system attacks corneal stromal proteins. Mooren ulcer is distinguished from other causes of peripheral ulcerative keratitis by the absence of associated systemic autoimmune or infectious disease. Two clinical subtypes are generally recognized. The first is a unilateral, limited form that tends to occur in older adults and responds relatively well to treatment. The second is a bilateral, aggressive form that is more common in younger patients, particularly in certain populations in sub-Saharan Africa and the Indian subcontinent, and is more resistant to therapy. Symptoms include severe eye pain, tearing, redness, photophobia (light sensitivity), and progressive visual impairment. The ulceration can lead to corneal thinning, descemetocele formation, and perforation if untreated. Treatment of Mooren ulcer is challenging and often requires a stepwise approach. Initial management may include topical corticosteroids and cyclosporine to suppress local inflammation. Surgical interventions such as conjunctival resection or excision of the limbal conjunctiva adjacent to the ulcer can be effective, particularly in the limited form. In refractory or aggressive cases, systemic immunosuppressive agents such as methotrexate, cyclophosphamide, or mycophenolate mofetil may be necessary. Corneal grafting (keratoplasty) may be required for perforation or severe thinning, though recurrence in the graft is possible. Despite treatment, the prognosis for the aggressive bilateral form remains guarded.
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Mooren ulcer.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Mooren ulcer at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Mooren ulcer.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Mooren ulcer.
Community
No community posts yet. Be the first to share your experience with Mooren ulcer.
Start the conversation →Latest news about Mooren ulcer
No recent news articles for Mooren ulcer.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Mooren ulcer
What is Mooren ulcer?
Mooren ulcer is a rare, chronic, painful, progressive ulcerative condition of the cornea (the clear front surface of the eye). It is characterized by peripheral corneal ulceration that typically begins at the limbus (the border between the cornea and the white of the eye) and progresses circumferentially and then centrally, potentially leading to severe vision loss or even perforation of the cornea. The ulcer is idiopathic but is believed to involve an autoimmune mechanism in which the body's immune system attacks corneal stromal proteins. Mooren ulcer is distinguished from other causes of per